Literature DB >> 18164597

Epidemiology and evaluation of chronic pelvic pain syndrome in men.

A J Schaeffer1.   

Abstract

Chronic pelvic pain syndrome (CPPS), formerly known as chronic abacterial prostatitis, is characterised by pelvic or perineal pain without evidence of urinary tract infection. It manifests as pain in a variety of areas including the perineum, rectum, prostate, penis, testicles and abdomen [Litwin MS, McNaughton-Collins M, Fowler Jr FJ, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 1999;2:369-75]. It is also frequently associated with symptoms including urinary urgency, frequency, hesitancy and poor or interrupted flow. CPPS may be associated with white cells in the prostatic secretions (inflammatory) (NIH-3A), or white cell absence in the prostatic secretions (non-inflammatory) (NIH-3B) [Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;3:236-7].

Entities:  

Mesh:

Year:  2008        PMID: 18164597     DOI: 10.1016/j.ijantimicag.2007.08.027

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

Review 1.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

2.  2018 CUA Abstracts.

Authors: 
Journal:  Can Urol Assoc J       Date:  2018-06       Impact factor: 1.862

3.  Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility.

Authors:  F Lotti; G Corona; G M Colpi; E Filimberti; S Degli Innocenti; M Mancini; E Baldi; I Noci; G Forti; L Adorini; M Maggi
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

4.  Differential expression of immune factor between patients with chronic prostatitis/chronic pelvic pain syndrome and the healthy volunteers.

Authors:  Chen Ye; Guang'an Xiao; Jian Xu; Shengfei Qin; Yuhua Luo; Guanghua Chen; H Henry Lai; Tie Zhou
Journal:  Int Urol Nephrol       Date:  2017-12-12       Impact factor: 2.370

5.  Circumcision plus antibiotic, anti-inflammatory, and α-blocker therapy for the treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, multicenter trial.

Authors:  Yuyang Zhao; Wei Zhao; Genqiang Lang; Yaowu Chen; Jianxin Liu; Guozeng Wang; Xiaobing Ma; Min Gong; Dongliang Xu; Shujie Xia
Journal:  World J Urol       Date:  2014-07-01       Impact factor: 4.226

6.  Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation.

Authors:  Isabella M Fuentes; Angela N Pierce; Pierce T O'Neil; Julie A Christianson
Journal:  J Vis Exp       Date:  2015-08-13       Impact factor: 1.355

7.  Evaluation of chronic pelvic pain syndrome in men: is it chronic prostatitis?

Authors:  Raymond M Bernal; Michel A Pontari
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 8.  Chronic prostatitis: management strategies.

Authors:  Adam B Murphy; Amanda Macejko; Aisha Taylor; Robert B Nadler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Turn-amplitude analysis as a diagnostic test for myofascial syndrome in patients with chronic pelvic pain.

Authors:  Fernando Itza; Daniel Zarza; Jesús Salinas; Fernando Teba; Carmen Ximenez
Journal:  Pain Res Manag       Date:  2015 Mar-Apr       Impact factor: 3.037

10.  Influence of infection on the distribution patterns of NIH-Chronic Prostatitis Symptom Index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Authors:  V Magri; F M E Wagenlehner; E Marras; J W O VAN Till; J Houbiers; P Panagopoulos; G L Petrikkos; G Perletti
Journal:  Exp Ther Med       Date:  2013-06-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.